膀胱过度活动症是排尿功能障碍常见的临床表现之一，治疗目的在于抑制膀胱逼尿肌的过度活动，从而增加膀胱容量。其常伴有尿频和夜尿增多症状，可伴有急迫性尿失禁，严重影响患者的日常生活和社会活动，已成为困扰人们的一大疾病。近年来，一种具有强选择性的β₃肾上腺素能受体激动剂作为膀胱过度活动症的潜在治疗手段有了很大发展。vibegron是一种作用机制新颖的尿失禁治疗药物，改变了30多年来采用传统的抗胆碱药物治疗尿失禁的思路，从而提高膀胱的充盈以及贮尿能力。主要从药物概况、相关背景、合成路线、药理作用、临床研究、安全性等方面进行介绍。

Overactive bladder (OAB) is one of the common clinical manifestations of voiding dysfunction. The purpose of the treatment of OAB is to inhibit the excessive activity of bladder detrusor, thereby increasing bladder capacity. The symptoms of OAB often are accompanied by urinary frequency, excessive urination, and urge incontinence, which seriously affect patient's daily life and social activities. OAB has become a major disease in people. In recent years, a kind of highly selective β₃ adrenergic agonist has made great development as a potential treatment of OAB. vibegron is a kind of urinary incontinence drugs with novel mechanism of action, which changes the idea for the treatment of urinary incontinence more than 30 years, so as to improve the filling of the bladder and urine storage capacity. The drug situation, background, route of synthesis, pharmacological action, clinical research, and safety of vibegron are reviewed in this paper.